• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自由能计算为选择性聚(ADP-核糖)聚合酶-1抑制剂的作用机制提供了深入见解。

Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.

作者信息

Cao Ran

机构信息

Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China.

出版信息

J Mol Model. 2016 Apr;22(4):74. doi: 10.1007/s00894-016-2952-x. Epub 2016 Mar 12.

DOI:10.1007/s00894-016-2952-x
PMID:26969680
Abstract

Selective poly (ADP-ribose) polymerase (PARP)-1 inhibitor represents promising therapy against cancers with a good balance between efficacy and safety. Owing to the conserved structure between PARP-1 and PARP-2, most of the clinical and experimental drugs show equivalent inhibition against both targets. Most recently, it's disclosed a highly selective PARP-1 inhibitor (NMS-P118) with promising pharmacokinetic properties. Herein, we combined molecular simulation with free energy calculation to gain insights into the selective mechanism of NMS-P118. Our results suggest the reduction of binding affinity for PARP-2 is attributed to the unfavorable conformational change of protein, which is accompanied by a significant energy penalty. Alanine-scanning mutagenesis study further reveals the important role for a tyrosine residue of donor loop (Tyr889(PARP-1) and Tyr455(PARP-2)) in contributing to the ligand selectivity. Retrospective structural analysis indicates the ligand-induced movement of Tyr455(PARP-2) disrupts the intra-molecule hydrogen bonding network, which partially accounts for the "high-energy" protein conformation in the presence of NMS-P118. Interestingly, such effect isn't observed in other non-selective PARP inhibitors including BMN673 and A861695, which validates the computational prediction. Our work provides energetic insight into the subtle variations in the crystal structures and could facilitate rational design of new selective PARP inhibitor.

摘要

选择性聚(ADP - 核糖)聚合酶(PARP)-1抑制剂是一种很有前景的癌症治疗药物,在疗效和安全性之间取得了良好的平衡。由于PARP - 1和PARP - 2之间结构保守,大多数临床和实验药物对这两个靶点的抑制作用相当。最近,一种具有良好药代动力学特性的高选择性PARP - 1抑制剂(NMS - P118)被披露。在此,我们将分子模拟与自由能计算相结合,以深入了解NMS - P118的选择性机制。我们的结果表明,对PARP - 2结合亲和力的降低归因于蛋白质不利的构象变化,这伴随着显著的能量惩罚。丙氨酸扫描诱变研究进一步揭示了供体环中一个酪氨酸残基(PARP - 1中的Tyr889和PARP - 2中的Tyr455)在决定配体选择性方面的重要作用。回顾性结构分析表明,NMS - P118存在时,PARP - 2的Tyr455的配体诱导运动破坏了分子内氢键网络,这部分解释了“高能”蛋白质构象。有趣的是,在包括BMN673和A861695在内的其他非选择性PARP抑制剂中未观察到这种效应,这验证了计算预测。我们的工作为晶体结构中的细微变化提供了能量见解,并有助于合理设计新的选择性PARP抑制剂。

相似文献

1
Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.自由能计算为选择性聚(ADP-核糖)聚合酶-1抑制剂的作用机制提供了深入见解。
J Mol Model. 2016 Apr;22(4):74. doi: 10.1007/s00894-016-2952-x. Epub 2016 Mar 12.
2
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.2-[1-(4,4-二氟环己基)哌啶-4-基]-6-氟-3-氧代-2,3-二氢-1H-异吲哚-4-甲酰胺(NMS-P118)的发现:一种用于癌症治疗的强效、口服可用且高度选择性的PARP-1抑制剂。
J Med Chem. 2015 Sep 10;58(17):6875-98. doi: 10.1021/acs.jmedchem.5b00680. Epub 2015 Aug 26.
3
Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.基于结构的药效团研究,以鉴定可能的天然选择性 PARP-1 捕获剂作为抗癌剂。
Comput Biol Chem. 2019 Jun;80:314-323. doi: 10.1016/j.compbiolchem.2019.04.018. Epub 2019 May 2.
4
Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective.NMS-P118与PARP-1和PARP-2选择性结合的分子机制:计算视角
Front Mol Biosci. 2020 Apr 15;7:50. doi: 10.3389/fmolb.2020.00050. eCollection 2020.
5
Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.人 PARP2 催化结构域与 PARP 抑制剂 ABT-888 复合物的晶体结构
Biochemistry. 2010 Feb 16;49(6):1056-8. doi: 10.1021/bi902079y.
6
In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.为设计高亲和力PARP-1抑制剂对全酶和脱辅基状态下PARP-1催化结构域进行计算机模拟研究。
J Enzyme Inhib Med Chem. 2016;31(1):112-20. doi: 10.3109/14756366.2015.1005011. Epub 2015 Jun 17.
7
Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.通过比较和经过验证的计算建模技术和分子动力学模拟,逐步开发出不同 PARP-1 抑制剂的结构-活性关系。
J Biomol Struct Dyn. 2015;33(8):1756-79. doi: 10.1080/07391102.2014.969772. Epub 2014 Oct 28.
8
Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.聚(ADP - 核糖)聚合酶(PARP)抑制剂的建模。配体对接与定量构效关系分析。
J Med Chem. 2001 Nov 8;44(23):3786-94. doi: 10.1021/jm010116l.
9
Exploring the effect of PARP-1 flexibility in docking studies.探讨 PARP-1 柔性在对接研究中的作用。
J Mol Graph Model. 2013 Sep;45:192-201. doi: 10.1016/j.jmgm.2013.08.006. Epub 2013 Sep 3.
10
Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.对比几种 2,4,6-三取代苯并咪唑的组蛋白去乙酰化酶和聚(ADP-核糖)聚合酶活性。
Chem Biol Drug Des. 2018 Jan;91(1):213-219. doi: 10.1111/cbdd.13072. Epub 2017 Aug 9.

引用本文的文献

1
PARP inhibitors in gastric cancer: beacon of hope.PARP 抑制剂在胃癌中的应用:希望的灯塔。
J Exp Clin Cancer Res. 2021 Jun 24;40(1):211. doi: 10.1186/s13046-021-02005-6.

本文引用的文献

1
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.2-[1-(4,4-二氟环己基)哌啶-4-基]-6-氟-3-氧代-2,3-二氢-1H-异吲哚-4-甲酰胺(NMS-P118)的发现:一种用于癌症治疗的强效、口服可用且高度选择性的PARP-1抑制剂。
J Med Chem. 2015 Sep 10;58(17):6875-98. doi: 10.1021/acs.jmedchem.5b00680. Epub 2015 Aug 26.
2
Predicting Molecular Targets for Small-Molecule Drugs with a Ligand-Based Interaction Fingerprint Approach.基于配体相互作用指纹图谱方法预测小分子药物的分子靶点
ChemMedChem. 2016 Jun 20;11(12):1352-61. doi: 10.1002/cmdc.201500228. Epub 2015 Jul 17.
3
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.
PARP-2通过限制红系祖细胞中的复制应激来维持小鼠的红细胞生成。
Cell Death Differ. 2015 Jul;22(7):1144-57. doi: 10.1038/cdd.2014.202. Epub 2014 Dec 12.
4
Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.癌症中多聚(ADP - 核糖基)化的抑制:对新旧范式的重新审视
Biochim Biophys Acta. 2014 Aug;1846(1):201-15. doi: 10.1016/j.bbcan.2014.07.004. Epub 2014 Jul 12.
5
Evaluation and application of MD-PB/SA in structure-based hierarchical virtual screening.
J Chem Inf Model. 2014 Jul 28;54(7):1987-96. doi: 10.1021/ci5003203. Epub 2014 Jul 8.
6
Insights into PARP Inhibitors' Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays.利用荧光偏振和表面等离子体共振结合测定法深入了解聚(ADP-核糖)聚合酶(PARP)抑制剂的选择性
J Biomol Screen. 2014 Sep;19(8):1212-9. doi: 10.1177/1087057114538319. Epub 2014 Jun 10.
7
New PARP targets for cancer therapy.用于癌症治疗的新型聚(ADP - 核糖)聚合酶靶点。
Nat Rev Cancer. 2014 Jul;14(7):502-9. doi: 10.1038/nrc3748. Epub 2014 Jun 5.
8
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.BMN 673,一种新型高效的 PARP1/2 抑制剂,用于治疗具有 DNA 修复缺陷的人类癌症。
Clin Cancer Res. 2013 Sep 15;19(18):5003-15. doi: 10.1158/1078-0432.CCR-13-1391. Epub 2013 Jul 23.
9
Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.通过基于结构的层次虚拟筛选发现新型微管蛋白抑制剂。
J Chem Inf Model. 2012 Oct 22;52(10):2730-40. doi: 10.1021/ci300302c. Epub 2012 Oct 2.
10
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.全家族 PARP 和 tankyrase 抑制剂的化学特征分析和结构分析。
Nat Biotechnol. 2012 Feb 19;30(3):283-8. doi: 10.1038/nbt.2121.